Dawn Holt

TL;DR: The relationship of CXCR3 expression to clinical outcome in 75 women diagnosed with early-stage breast cancer and the antimetastatic effect of CxCR3 gene silencing was compromised in mice depleted of Natural Killer cells or with mutations in IFN-γ, suggest that the role of C XCR3 is not simply to mediate tumor cell trafficking.

TL;DR: While preclinical and epidemiological data support the use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors (COXibs) for the prevention and treatment of malignancy, toxicities due to COXIBs as well as less than promising results from clinical trials have laboratories seeking alternative targets.

TL;DR: A mechanism whereby inhibiting PGE2 production or preventing signaling through the EP4 receptor may prevent suppression of NK functions that are critical to the control of breast cancer metastasis is supported.

TL;DR: The findings reveal that EP4 antagonism prevents tumor-mediated NK-cell immunosuppression and demonstrates the anti-metastatic activity of a novel EP4 antagonist, which support the investigation of EP4 antagonists in clinical trials.

TL;DR: It is shown that NK functions are depressed in tumor-bearing hosts relative to normal NK cells and that PGE2 suppresses NK functions by acting on EP2 and EP4 receptors.